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Key Points
• The integrin Mac-1
I-domain interaction
with platelet receptor
GPIba has been
mapped by NMR.
• The GPIba LRR cap-
ping a-helix coordi-
nates directly to the
Mac-1 MIDAS Mg21
ion via an acidic
residue.
Cell-surface receptor interactions between leukocyte integrin macrophage-1 antigen
(Mac-1, also known as CR3, aMb2, CD11b/CD18) and platelet glycoprotein Iba (GPIba)
are critical to vascular inﬂammation. To deﬁne the key residues at the binding
interface, we used nuclear magnetic resonance (NMR) to assign the spectra of the mouse
Mac-1 I-domain and mapped the residues contacting the mouse GPIba N-terminal domain
(GPIbaN) to the locality of the integrin metal ion-dependant adhesion site (MIDAS) surface.
We next determined the crystal structures of the mouse GPIbaN and Mac-1 I-domain to
2 A˚ and 2.5 A˚ resolution, respectively. The mouse Mac-1 I-domain crystal structure reveals
an active conformation that is stabilized by a crystal contact from the a7-helix with a
glutamate side chain completing the octahedral coordination sphere of the MIDASMg21 ion.
The amino acid sequence of the a7-helix and disposition of the glutamic acid matches the
C-terminal capping region a-helix of GPIba effectively acting as a ligand mimetic. Using
these crystal structures in combination with NMR measurements and docking analysis,
we developed a model whereby an acidic residue from the GPIba leucine-rich repeat (LRR)
capping a-helix coordinates directly to the Mac-1 MIDAS Mg21 ion. The Mac-1:GPIbaN
complex involves additional interactions consolidated by an elongated pocket ﬂanking
the GPIbaN LRR capping a-helix. The GPIbaN a-helix has an HxxxE motif, which is
equivalent by homology to RxxxD from the human GPIbaN. Subsequent mutagenesis of
residues at this interface, coupled with surface plasmon resonance studies, conﬁrmed
the importance of GPIbaN residues H218, E222, and the Mac-1 MIDAS residue T209 to
formation of the complex.
Introduction
The integrin receptor macrophage-1 antigen (Mac-1, also known as CR3, integrin aMb2, or CD11b/CD18)
is expressed on the surface of myeloid leukocytes and mediates numerous responses of these cells critical
to innate immunity.1 TheMac-1 receptor contributes to the recruitment, firm adhesion, and transendothelial
migration of leukocytes at sites of vascular injury and facilitates tissue inflammation.2 Biochemical and cell-
based studies have characterized the interactions of the Mac-1 integrin with diverse ligands, including
plasma protein fibrinogen,3 complement protein fragment iC3b,4 high-molecular-weight kininogen ,5 and
the cell-surface receptors platelet glycoprotein Iba (GPIba)2 and intercellular adhesion molecule 1 (ICAM-1).6
The Mac-1 integrin exists in an inactive conformation and, when activated by a variety of stimuli, undergoes
a structural change to an active form capable of binding to ligands with high affinity.7,8 Concurrently,
allosteric changes occur on ligand binding that result in “outside-in” cell signaling.9
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Mac-1–deficient mice show delayed thrombosis, but largely unimpaired
hemostasis.10 Blocking the Mac-1:GP1ba interaction prevents neutro-
phil extracellular trap formation,11 and an antibody targeting Mac-1 was
shown to block inflammation.12 Inhibiting the Mac-1 I-domain with the
small molecule allosteric regulator leukaderin-1 has demonstrated
efficacy in animal models of inflammatory disease.13,14
For the majority of Mac-1 interactions described, the inserted
aM-subunit, or “I-domain,” is the principal ligand-binding domain.
The Mac-1 I-domain contains a Mg21 binding site on its surface at
the top of the b sheet called the metal ion-dependant adhesion site
(MIDAS), which is capable of accepting the side chain of an acidic
residue (aspartate or glutamate) from coordinating ligands.1,7 A
crystal structure has defined the interaction between Mac-1 and
iC3b,4 but the complex between Mac-1 and GPIba and the principal
ligand fibrinogen3 are poorly understood at the molecular level. Here,
nuclear magnetic resonance (NMR) assignment of the mouse Mac-1
I-domain, together with X-ray structural analysis of both the mouse
GP1baΝ and Mac-1 I-domain, has enabled us to map the binding
surface and model the interaction site for the GP1ba leucine-rich
repeat (LRR) N-terminal domain (GP1baN) with the MIDAS face
of Mac-1.
Materials and methods
Protein expression, purification, and characterization
A complementary DNA fragment encoding mouse GP1baN residue
E1 to T266 (mature protein sequence numbering) was cloned
into the pMT-puro vector for expression using the DES system
(Invitrogen). At the N terminus, the signal sequence corresponds to a
Drosophila homolog of the immunoglobin binding chaperone protein
secretion signal, and a polyhistidine tag sequence TRTGHHHHHH
was added at the C terminus. Site-specific mutations H218A and
E222A were introduced using the QuikChange method (Stratagene)
and confirmed by DNA sequencing. The mouse amino acid sequence
numbering is defined by alignment with the mature human GP1ba
sequence, such that H218 corresponds to H234 in the UniProt
numbering of entry GP1BA_MOUSE, which includes the signal
sequence. Drosophila S2 cells were grown in Dulbecco’s modified
Eagle medium supplemented with 10% fetal bovine serum at 28°C
and transfection was performed in each case using calcium phosphate.
Cells were grown for an additional 48 hours before selection with
puromycin to establish stable cell lines. Serum-free Express Five
(Invitrogen) insect culture media was collected containing secreted
proteins. Initial capture of the crude product was performed using
Ni-sepharose affinity chromatography, followed by gel filtration and
ion exchange chromatography (supplemental Figure 1). Protein
identity and successful removal of the signal peptide was confirmed
by trypsin digest mass spectrometry, analyzed using the Mascot
Database (ProteinID, University of York) shown in supplemental
Figures 1 and 2.
The mouse Mac-1 I-domain gene fragment (P129 to A318; mature
protein sequence numbering) was cloned into the pGEX-4T-1 vector,
for expression as an N-terminal GST-fusion using Escherichia coli. All
mutants were produced using Q5 site-directed mutagenesis. XL1-
Blue and BL21 cells were transformed using calcium chloride for
storage and expression, respectively. BL21 cells were grown in LB
media (for surface plasmon resonance [SPR] and mass spectrom-
etry) or M9 minimal media (for NMR spectroscopy) supplemented
with 15N ammonium chloride and/or 13C glucose as required for
isotope labeling. GST-affinity chromatography and incubation with
thrombin resulted in the separation of the tag (residual Gly-Ser remains
at the N terminus) and further purification using cationic exchange
chromatography. Mass spectrometry, gel filtration studies, NMR
line width analysis, and diffusion measurements indicate that the
recombinant Mac-1 I-domain is monomeric in solution (supple-
mental Figures 3 and 4).
NMR spectroscopy
NMR data were recorded at 25°C on a Bruker 800 MHz Avance III
spectrometer with a QCI cryoprobe using Topspin 3.1 software.
Backbone resonances (13C/15N) were assigned using HNCO,
HN(Ca)CO, CbCaNH, and CbCa(CO)NH experiments. Backbone
assignment (.146/182 residues) was facilitated by a number of
locally perturbing single-point mutations (to Ala/Gly) and through
selective unlabeling experiments (Glu and Lys, in particular). 15N-TROSY
2D spectra were collected in titration experiments at a Mac-1
concentration of 120 mM in 25 mM potassium phosphate buffer
(pH 7.0), 25 mM NaCl, 5% D2O, and 0.02% NaN3 using 1.5
equivalents of MgCl2 to ensure metal complexation.
15N-TROSY
spectra were collected at 0.2 molar ratio intervals up to a 2:1
excess of GPIbaN. Chemical shift perturbations (CSPs) were
calculated using a weighting of 1H and 15N shifts according to:
CSP5√ [1/23 (dH21 0.143 dN2)]. For structural modeling, the
standard deviation (SD) from the mean CSP was calculated and
mean 1 SD and mean 1 2 3 SD used for surface mapping.
Quantitation of Mac-1 I-domain ligand binding
SPRwas performed using a BIAcore 3000 (GE Healthcare). Ligands
of recombinant mouse GPIbaN, GPIbaN variants H218A and
E222A, and fibrinogen (s) were amine-coupled to a CM5 sensor chip
(GE Healthcare); a reference cell was prepared by blank amine-
coupling. Recombinant Mac-1 I-domain wild-type and T209A variant
samples at protein concentrations ranging from 3.125 mM to
200 mM, in running buffer (10 mM N-2-hydroxyethylpiperazine-N9-
2-ethanesulfonic acid, pH 7.4, 140 mM NaCl, 1 mM MgCl2) were
injected at a flow rate of 50 mL/min. Kinetic studies of the Mac-1
I-domain wild-type and T209A constructs were conducted as a
dilution series, in the presence and absence of Mg21 against the
immobilized GPIbaN. Each of the series contains a minimum of
10 concentrations (11.25-200 mM) and was repeated a minimum of
2 times. The Mg21 ion dependence of the GPIbaN interaction was
tested against a wild-type Mac-1 I-domain concentration series
(6-100 mM) in which the running buffer contained 5 mM EDTA to
sequester metal ions. Binding to the immobilized GPIbaN was
also evaluated using a dilution series of the antibody Xia.B2 (emfret
ANALYTICS) with protein concentration of 3 to 50 nM. The CM5 chip
was regenerated with 2 M NaCl after each experiment. Binding
curves were generated by subtracting the appropriate controls and
the resulting curves were analyzed using BIAevaluation software or
a steady-state equilibrium approach using a Hill plot generated
with Prism 6 (GraphPad Software Inc.).
Protein crystallization and crystal
structure determination
Recombinant mouse GP1baN was concentrated to 12 mg/mL and
subjected to sparse matrix screens of Morpheus, Proplex, Index,
PACT, JCSG1, and MIDAS using the sitting drop vapor diffusion
method. Crystals of GP1baN grew in Morpheus condition D2
containing 0.2 Mmixture of 1,6-hexanediol; 1-butanol; 1,2-propanediol;
14 MAY 2019 x VOLUME 3, NUMBER 9 Mac-1 I-DOMAIN INTERACTION WITH GPIbaN 1451
.For personal use onlyon May 9, 2019. by guest  www.bloodadvances.orgFrom 
2-propanol; 1,4-butanediol; 1,3-propanediol, 0.1 M imidazole; MES
monohydrate (acid) pH 6.5, 20% v/v ethylene glycol; and 10% w/v
PEG 8000. Crystals of the mouse Mac-1 I-domain (6 mg/mL) grew in
the JCSG1 screen condition D7, 0.2 M lithium sulfate, 0.1 M
tris(hydroxymethyl)aminomethane, pH 8.5, 40% PEG 400. Crystals
were cryocooled in liquid nitrogen and X-ray diffraction data were
collected using the ID30B beamline at the ESRF (GP1baN) and
Diamond beamline I24 (Mac-1 I-domain). Data were processed
with XDS and molecular replacement was performed with PHASER
using a human GP1baN15 and Mac-1 I-domain structure7 (Table 1).
Partial model building was performed using BUCCANEER and
completed manually using COOT and refined with REFMAC5
(deposited PDB code: 6EJX).
Molecular docking calculations
Three-dimensional models of the Mac-1 I:GPIbaN docked complex
structures were calculated using HADDOCK16 with template Mac-1
I-domain (PDB code: 1IDO) and GPIbaN (PDB code: 1M0Z) crystal
structures used. Active residues were defined based on the Mac-1
I-domain NMR titration experiments: E244, G143, and N147 plus the
MIDAS Mg21 ion. Active residues for GPIbaN were D222 and R218.
Results
NMR assignment and structural analysis of the
Mac-1 I-domain
A bacterially expressed mouse Mac-1 I-domain construct (residues
129-318) was isotopically (13C/15N) labeled and the NMR spectra
assigned using heteronuclear 3-dimensional NMR experiments. The
1H/15N heteronuclear single quantum coherence is highly dispersed
with sharp resonances indicative of well-ordered secondary structure
in both the Mg21 free and bound state (supplemental Figure 5). We
also prepared and characterized 2 Mac-1 mutants, T209A and
F302W, which have previously been reported as “inactive” (T209A)
and “pseudo-open” (F302W) variants of the I-domain.17,18 The side
chain of T209 coordinates directly with the Mg21 ion only in
the “open” conformation of the Mac-1 I-domain,4,7 and previous
crystallographic studies have defined a large allosteric conforma-
tional shift between “open” and “closed” states, which links the
switching of the coordination of the metal ion from D140 to T209 to
a shift in the position of helix a7.7,19 T209 has also been shown to
play a direct and critical role in Mac-1 ligand binding to ICAM-1 and
iC3b.6 The CD spectra of the mutants and wild-type Mac-1 are
superimposable, showing no significant changes in protein second-
ary structure and folding (supplemental Figure 1B). NMR of the
15N-labeled mutant proteins confirms retention of the core structure;
however, extensive perturbations across the MIDAS face are evident
in both mutants (supplemental Figure 5).
NMR analysis of the Mac-1 I-domain interaction
with GP1baN
Recombinant mouse GP1baN was expressed and purified from
insect cells (supplemental Figures 1 and 2). NMR chemical shifts
(1H/15N) are particularly sensitive to changes in chemical environ-
ment and the conformation associated with ligand binding and were
used to characterize the GP1baN interaction with the Mac-1 I-domain.
A buffered solution of GP1baN was titrated into a 120 mM solution of
15N-Mac-1 I-domain in the presence of 1.5 molar equivalents of Mg21,
and 1H/15N heteronuclear single quantum coherence spectra were
collected over a range of ligand concentrations up to a Mac-1
I:GP1baN molar ratio of 1:2.
A significant number of fast-exchange CSPs are observed in
response to ligand binding. However, a number of residues within
the Mac-1 I-domain C-terminal region (helix a7) showed some
evidence of signal broadening and peak distortion in the bound state.
Statistically significant CSP effects are identified for 16 residues of
the Mac-1 I-domain (Figure 1) and enable us to identifying 2 well-
defined binding patches. The first group of residues, which are in
close proximity or intimately involved in MIDAS Mg21 coordination,
includes D140, S142, G143, I145, and D242 together with the
adjacent solvent-exposed residues N147, K210, and E244.
Residues D242, E244, and D273 cluster on the surface of the
I-domain to form a negatively charged patch that is adjacent to
the MIDAS. The second group of Mac-1 residues I265, R266,
F275, G293, E294, H295, and V296 (Figure 1D-E) are distal to the
MIDAS and appear to be linked to it through conformational changes
propagated away from the metal center.
Crystal structures of the mouse GP1baN and
Mac-1 I-domain
We next determined the crystal structure of mouse Mac-1 I-domain
to 2.5 A˚ resolution. This revealed the mouse Mac-1 I-domain in an
open conformation with the MIDAS metal ion coordinated by T209,
S142, S144, and a glutamic acid residue (E314) ligand mimetic
supplied by a crystal contact from the C-terminal helix (a7) of the
Table 1. Crystallographic data collection and refinement statistics
Sample Mouse GP1baN Mouse Mac-1 I
Data collection
Space group P212121 P41212
Cell dimensions
a, b, c (A˚) 61.5, 72.8, 164.0 62.9, 62.9, 336.2
a, b, g (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Resolution, A˚ 29.9-2.0 45.9-2.5
Rmerge* 11.1 12.5
I/sI; CC(1/2)† 7.0 (1.9); 0.997 (0.78) 8.2 (1.5); 0.903 (0.68)
Completeness (%)† 99.0 (90.0) 86.7 (67.2)
Redundancy† 4.3 (1.3) 6.2 (2.5)
Refinement
Number of reflections 48095 21236
Rwork/Rfree‡ 0.192/0.237 0.222/0.271
B factors, A˚2
Protein 29.8 48.2
RMS deviations
Bond lengths, A˚ 0.018 0.021
Bond angles, ° 1.96 1.85
RMS, root mean square.
*Rmerge 5 Sum(h) [Sum(j) [I(hj) 2 ,Ih.]/Sum(hj) ,Ih., where I is the observed intensity
and ,Ih. is the average intensity of multiple observations from symmetry-related reflections
calculated with SCALA.
†Values in parentheses are for the highest resolution shell.
‡Rwork 5 Sum(h) ||Fo|h 2 |Fc|h| / Sum(h)|Fo|h, where Fo and Fc are the observed and
calculated structure factors, respectively. Rfree computed as in Rwork, but only for 5%
randomly selected reflections, which were omitted in refinement, calculated using
REFMAC.
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Figure 1. Mapping the Mac-1 I-domain binding site with GP1baN by NMR. (A) Selected peaks showing CSP effects between bound and unbound (the first panel for
G228 is shown as a control, in which no perturbation is observed). (B) Representation of CSP effects, with dashed lines showing statistically significant perturbation (lower
line, mean CSP 11 SD; upper line, mean CSP 12 SD) residues above the latter. (C) CSP effects mapped to the Mac-1 surface with residues in darker pink corresponding to
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I-domain (orange in Figure 2A; supplemental Video 1). The C-terminal
Mac-1 I-domain a-helix consists of the amino acid sequence 310-
NQLQE-314, which resembles the sequence from the a-helix in the
GPIbaN capping region spanning residues 218-HWLQE-222, and is
equivalent structurally in terms of the a-helical disposition of the
glutamic acid residue. Figure 2B shows that the a-helix sits in a groove
on the surface of the Mac-1 I-domain packing against residues F246
and R208, forming multiple hydrogen bonded contacts between the
sidechains of N310 and N306 and the sidechains of E244 and K277
on the MIDAS face. For comparison, crystal structures are available for
the human Mac-1 I-domain as an open conformation in complex with
ligand iC3b,4 simvastatin,20 and stabilized by a crystal contact.7,8
The mouse and the human Mac-1 I-domain crystal structures are
superposed in Figure 2D, revealing the MIDAS metal ion coordinating
acidic residue consistently occupies an identical position simulta-
neously bonding to both the metal ion and the hydroxyl of T209. Subtle
differences occur across the MIDAS face with the introduction of
K277 in the mouse Mac-1 forming a salt bridge to E244, replacing the
K279-E244 salt bridge observed in the human structure (Figure 2C).
We then determined the crystal structure of the mouse GP1baN to
2.0 A˚ resolution to examine the conformation of the LRR C-terminal
capping a-helix, which is important for the interaction with Mac-1.2
This structure reveals overall features of the LRR solenoid flanked
by N- and C-terminal disulphide-bonded capping regions and
R-loop, as observed previously for the human GP1baN structure.21
The junction between the C-terminal capping region a-helix and
the LRR solenoid forms an elongated pocket (Figure 3A, dotted
elliptical line). In a notable departure from the human sequence,
Figure 3B-D reveals that the mouse GP1baN has the substitu-
tions H218 and E222 that, by analogy with the human GP1baN
structure, are also surface exposed (Figure 3B). A comparison of
structures shows that mouse GP1baN H218 and E222 occur
with the same disposition as human GP1baN R218 and D222,
respectively, and a sequence alignment of this region reveals that
charged residues at these positions are conserved across other
mammalian species (Figure 3C).
Docking of the GPIbaN and Mac-1 I-domain
3-dimensional structures
Previous cell-based and biochemical studies identified residues 218
through 228 from GP1ba as the principal determinants of the Mac-1
interaction2 encompassing the human GP1baN LRR C-terminal
Figure 1. (continued) mean 12 SD, top-down view onto the MIDAS (Mg21 shown in yellow). (D) Side view showing distal CSP effects removed from the MIDAS site (top).
(E) Surface representation showing the binding patch around the MIDAS with key residues in red. (F) Differentiation between the MIDAS binding patch, shown in red, and
those distal residues (in green) affected through allosteric changes from binding GP1baN at the MIDAS site (a few key residues are highlighted).
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Figure 2. Crystal structure of the mouse Mac-1 I-domain.
(A) A cartoon diagram is shown for the crystal structure of the
mouse Mac-1 I-domain (purple) with the crystal contact
stabilizing the active conformation derived from the C-terminal
helix a7 in orange. The MIDAS bound Mg21 ion is shown as a
sphere (green) and key residues are shown as sticks and
electrostatic interactions as dashed magenta lines. (B)
A close-up view of the MIDAS site with residues from helix a7
labeled. (C) A second view of the Mac-1 I-domain MIDAS site
with the crystal contact residue E314 shown coordinating the
Mg21 ion and the sidechain hydroxyl of T209. (D) Superposition
of the human (gray) and mouse (purple) crystal structures in the
region of the MIDAS face. The stabilization glutamic acid is
shown as sticks in cyan (human) and orange (mouse).
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capping a-helix, but did not specify whether a critical acidic residue
was involved. Studies using a variety of techniques implicated Mac-1
as residing on the MIDAS face and residues T213 and R216 as being
located away from the MIDAS face, but did not propose a role for
the Mg21 ion or an overall model for the complex with GP1baN.10,22
We thus set out to investigate this by generating models of the
Mac-1 I:GP1baN complex using the program HADDOCK.16 Multiple
crystal structures are available for the human Mac-1 I-domain in the
open conformation4,7,8,18,23 and human GP1baN domain,15,21,24-26
and they were used as templates for docking.
Docking was performed using NMR distance restraints between
the Mac-1 MIDASMg21 ion and residues G143, N147, D242, and
E244, which were identified as having significant CSP effects in
the NMR titration experiments, together with GP1baN surface-
exposed residues R218, D222, and N223.2 The top scoring structure
and details of the interface are shown in Figure 4A. The Mac-1
I:GP1baN complex buries a surface area of 593 A˚2 (calculated using
PISA), and 2 key features that define the unique orientation are that
GP1baN D222 coordinates to the Mac-1 MIDAS Mg21 ion and
GP1baN R218 forms bidentate salt bridges with Mac-1 residues
D242 and E244 (supplemental Videos 2 and 3). As viewed down
the central projection of the GP1baN capping a-helix, colored
orange in Figure 4B, residues G143 and S144 of Mac-1 (lower left)
hydrogen bond to the side chains of N221 and R217 of GP1ba,
respectively. Flanking interactions also occur on the right of Figure 4B
as R208 from Mac-1 forms hydrogen bonds to the side chains of
N223 of GP1ba, and its own H195 main chain carbonyl. The Mac-1
I-domain F246 side chain inserts into an elongated hydrophobic
pocket in the GP1baN LRR capping region defined by GP1ba
residues F192, S194, Y215, and W219 (Figure 4C).
SPR analysis of the Mac-1 I:GPIbaN interaction
To further evaluate the contribution of amino acid side chains at the
center of the proposed mouse Mac-1 I:GP1baN interface, we used
site-directed mutagenesis coupled with SPR. To establish the assay,
the SPR response was first observed with Mac-1 I-domain analyte
and immobilized full-length fibrinogen, which has been characterized
in detail from previous studies.3 SPR analysis (Figure 5A) shows a
high-affinity interaction with evidence of multiple binding modes; an
estimated Kd of 30 mM was derived from the equilibrium values of
response units was consistent with previous reports.3
A ligand surface of GPIbaN was generated through amine-coupling
to a CM5 chip. To determine the integrity of the GPIbaN surface, a
dilution series with the antibody Xia.B2 (emfret ANALYTICS) was
conducted and analysis of sensorgrams resulted in a Kd of 34 nM,
consistent with the anticipated high affinity for an antibody-antigen
interaction, confirming the immobilized GPIbaN is forming an
active surface. Sensorgrams were recorded using wild-type Mac-1
I-domain as the analyte and high-quality SPR curves were obtained
(Figure 5B, top), such that association and dissociation profiles
fitted well to a 1:1 Langmuir simultaneous binding model. A
calculated Kd of 64 mM was in good agreement with the steady-
state equilibrium Kd value of 121 mM.
Our model of the Mac-1 I:GPIbaN complex shows that the Mac-1
I-domain T209 is a pivotal residue at the binding interface not only
GPIbN GPIbN pocket
E222
E222
H218
H218
C
B
A
Figure 3. Crystal structure of the mouse GP1baN. (A) A
cartoon diagram is shown for the crystal structure of the mouse
GPIbaN with the C-terminal LRR capping a-helix colored
orange and R-loop colored yellow. GPIba residues H218 and
E222 involved in the interaction with Mac-1 are shown as sticks.
The elongated pocket formed in the GPIba LRR capping region
is indicated by a dashed line and represented as a transparent
charged surface with key residues lining the pocket shown as
sticks. (B) Electron density (2Fo-Fc) from the crystal structure of
the mouse GPIbaN C-terminal capping a-helix residues H218
and E222 (gray mesh). (C) Amino acid sequence alignment of
GPIba residues 215 through 223 (human sequence numbering
without the signal sequence) from the GPIba LRR capping
a-helix for human, mouse, dog, and cow. Key charged residues
218 and 222 are colored blue and red, respectively.
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by coordinating the MIDASmetal ion, but also in forming a hydrogen
bond from the b-OH to the carboxylate of GPIbaN D222. The
binding to GPIbaN of the Mac-1 T209 alanine variant (T209A)
elicited neither a significant signal response nor a clear association
binding curve (Figure 5B, bottom), which was similarly the case
with wild-type Mac-1 with EDTA in excess (5 mM) to remove the
metal ion from the MIDAS (data not shown). These experiments
demonstrate that the bound Mg21 ion in the MIDAS is critical to
the interaction and confirm that the observed distal CSP effects
in the NMR titration data arise from allosteric effects propagated
away from the MIDAS site, rather than to a second ligand-binding
site. In contrast with GPIbaN, at least 1 of these binding interactions
is still evident from the SPR analysis with full-length fibrinogen and
Mac-1 T209A, although the overall binding affinity is greatly reduced
(Figure 5A, bottom). This is consistent with a primary binding site
around the MIDAS surface, along with a second, low-affinity Mac-1
I-domain site.3
We further tested the model of the Mac-1 I:GPIbaN complex by
generating recombinant mouse GP1baN variants H218A and
E222A, which were purified with a similar protocol and produced a
similar yield to the wild-type protein (supplemental Figure 1A). SPR
studies using the immobilized GPIbaN mutants with the wild-type
Mac-1 I-domain as the analyte revealed that GP1baN H218A and
E222A substitutions led to a loss of SPR response, preventing the
sensorgrams from being fitted using either kinetic or equilibrium
binding models, indicating significant impairment of the interaction
with the Mac-1 I-domain (Figure 5C).
Discussion
Interactions among innate immune cells, platelets, and plasma proteins
have been implicated in pathways leading to thrombosis,10,27-29 and yet
very few of these protein interactions have been fully described. To
the best of our knowledge, we provide the first detailed description of
the complex formed between the leukocyte integrin Mac-1 I-domain
and the platelet receptor GPIbaN using a combination of NMR,
crystallography, site-directed mutagenesis, and SPR binding
studies. We establish the principle that the Mac-1 I-domain in the
open conformation has a groove on the surface formed by the
extended sidechains of F246 and R208 and other residues that
can accommodate an a-helix appropriately positioned by an
acidic side chain coordinating the MIDAS metal ion and the side
chain hydroxyl of T209. We show that the GPIbaN receptor LRR
C-terminal capping a-helix uses a key acidic residue (D222 in
the human; E222 in the mouse ortholog) to coordinate to the
vacant site in the metal ion coordination shell of the Mac-1 MIDAS
Mg21 ion.
The presence of the integrin-binding acidic residue at the end of an
a-helix in GPIbaN is reminiscent of the crystal structure of the Mac-1
I-domain complex with iC3b, whereby the integrin MIDAS metal
ion binding residue D1247 of iC3b is also placed at the end of an
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Figure 4. The Mac-1 I:GP1baN complex. (A) A cartoon
diagram of the docked complex of the crystal structures of
human GPIbaN and the Mac-1 I-domain with the Mac-1
secondary structures colored blue/green and GPIbaN colored
red/orange. Boxed is a close-up view of the interface where the
Mg21 ion bound to the Mac-1 MIDAS site is shown as a sphere
and electrostatic interactions are shown as dashed purple lines.
The GPIbaN C-terminal LRR capping region is colored orange
and residue F192 from the LRRs is in gray. (B) A second view
related by a 90° rotation. GPIbaN residue D222 coordinates
the Mac-1 MIDAS Mg21 ion and surrounding residues on the
MIDAS surface (light blue). (C) Charged surface representation
of the GPIbaN LRR capping region showing an elongated
pocket formed by GPIba residues Y215, W219, and F192 is
flanked by a region of positive charge (GPIba R218) and
negative charge (GPIba D222) that form complementary
interactions with Mac-1 residues shown as sticks (light blue).
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a-helix.4 A comparison of the Mac-1 I:iC3b and Mac-1 I:GPIbaN
complexes reveals the MIDAS-coordinating a-helix is oriented
differently (90° rotation) in each ligand relative to the Mac-1
I-domain surface. In addition, unlike GP1baN, iC3b does not use
the negatively charged patch (E244) on the surface of the Mac-1
I-domain for binding, but in common with GP1baN it does use
Mac-1 I-domain residue R208.4 These interactions suggest
that the ability of the Mac-1 I-domain to bind a host of specific
ligands involves a common binding surface and fits with the
previously proposed mosaic model of Mac-1 ligand binding.30
By contrast, GPIbaN uses 3 spatially separated regions of
the receptor to bind the structurally distinct ligands of the von
Willebrand factor A1 domain24,26 (GPIba LRRs and R-loop),
thrombin25,31 (GPIba anionic region), and Mac-1 (GPIbaC-terminal
LRR cap).
The Mac-1 MIDAS interaction with an acidic residue from an a-helix
of the ligand contrasts to the closely related integrin leukocyte
function associated antigen-1 (LFA-1), which exploits a glutamate
residue located within a b strand of the ligand ICAM-132 to bind
the LFA-1 MIDAS a-subunit I-domain. A variety of studies have
defined a large allosteric conformational shift between open and
closed states of the leukocyte integrins Mac-1 and LFA-1 linked
to the disposition of a-I-domain helix a7 and switching of the
coordination shell within the MIDAS between D140 and T209.7,9
NMR studies have been previously reported for the related LFA-1
I-domain,33 but to date no NMR characterization has been
applied to Mac-1. LFA-1 does not bind GPIbaN, and a series of
LFA-1/Mac-1 chimeras have been used previously to localize the
binding site for GPIbaN within the Mac-1 I-domain to specific
residues. Many of these are consistent with the Mac-1:GP1baN
interface shown in Figure 4,22 but residues T213 and R216 are
not part of the MIDAS face of the Mac-1 I-domain structure.10 The
crystal structures of Mac-1 I-domain reveals the T213 side chain
hydroxyl group is buried and hydrogen bonded by contact with
the D248 side chain in both the open and closed conformation
and thus is not present on the surface to interact with a ligand.
Mac-1 residues T213 and R216 are very close to key MIDAS face
residues R208 and F246 and thus may affect binding indirectly,
or, alternatively, R216 could form part of a second binding site for
GP1baN.
Overall, we believe this is the first detailed description of the
interface formed between an integrin receptor and an LRR protein
revealing an elongated pocket in the GPIbaN LRRC-terminal capping
region, which is key to the interaction. The Mac-1 integrin is not
the only integrin to engage multiple ligands and, interestingly,
the more distantly related integrin a2b1 binds to collagen
19
as the principal ligand and has a well-characterized additional
interaction with the LRR C-terminal capping region of the
matrix protein chondroadherin.34 The binding site for the a2b1
integrin is localized to the chondroadherin sequence of residues
LRRWLEAK,34 which resembles the FRRWLQDN sequence we
report for GPIba. Chondroadherin crystal structures reveal the
LRRWLEAK sequence has an acidic residue that is surface
exposed within the a-helix of the LRR capping region in a similar
manner to GPIbaN. Previous authors also have speculated that the
groove adjacent to the a-helix could be used by the integrin as
described here.35,36 This structural scaffold describing an integrin-
LRR protein interaction will facilitate the development of agents
targeting Mac-1 or GPIbaN for the modulation of thrombotic and
inflammatory disorders.
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